[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-351665-en":59,"doc-seo-351665-105":98},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":41,"preview_page_count":19,"preview_urls":80},351665,687208528416,"Cipher","https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","The therapeutic value of antidiabetic drugs in lung cancer treatment: from clinical evidence to possible mechanisms","Rising burdens of lung cancer and diabetes mellitus have driven interest in whether hypoglycemic agents can provide anti-tumor benefit beyond glucose control. This mini review synthesizes recent clinical evidence and discusses how commonly used diabetes drugs, including metformin and other agents, may influence lung cancer through multi-pathway regulation. The review emphasizes potential complementary roles in combination regimens, aiming to improve chemotherapy and targeted therapy efficacy while supporting more precise treatment strategies and patient survival outcomes.","TYPE Mini Review  \nPUBLISHED 29 April 2026  \nDOI 10.3389/fimmu.2026.1805197  \nOPEN ACCESS  \nEDITED BY  \nXianhuo Wang,  \nTianjin Medical University Cancer Institute and Hospital, China  \nREVIEWED BY  \nDimitris Kounatidis,  \nLaiko General Hospital of Athens, Greece  \n*CORRESPONDENCE  \nYue Hu  \n[yuehu@jlu.edu.cn](yuehu@jlu.edu.cn)[ ](yuehu@jlu.edu.cn)Haixia Zhou  \n [zhouhaixia@jlu.edu.cn](zhouhaixia@jlu.edu.cn)[ ](zhouhaixia@jlu.edu.cn)†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 06 February 2026  \nREVISED 26 March 2026  \nACCEPTED 10 April 2026  \nPUBLISHED 29 April 2026  \nCITATION  \nWang Q, Xu J, Liu Q, Zhou H and Hu Y (2026) The therapeutic value of antidiabetic drugs in lung cancer treatment: from clinical evidence to possible mechanisms.  \nFront. Immunol. 17:1805197 .  \ndoi: 10.3389/fimmu.2026.1805197  \nCOPYRIGHT  \n© 2026 Wang, Xu, Liu, Zhou and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThe therapeutic value of antidiabetic drugs in lung cancer treatment: from clinical evidence to possible mechanisms  \nQian Wang 1,2†, Jiayi Xu 1,2†, Qing Liu 1,3, Haixia Zhou 1,4* and Yue Hu 1,5*  \n1China-Japan Union Hospital of Jilin University, Changchun, China, 2 Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, China, 3 Department of Endocrinology and Metabolism, China-Japan Union Hospital of Jilin University, Changchun, China, 4 Department of VIP, China-Japan Union Hospital of Jilin University, Changchun, China, 5 Department of Biobank, China-Japan Union Hospital of Jilin University, Changchun, China  \nWith the steadily rising incidence of lung cancer and diabetes mellitus, both of them are increasingly becoming prominent global health concerns. Treatment options for lung cancer to improve prognosis and reduce the pain and ﬁnancial burden of patients remain under continuous exploration. In recent years, hypoglycemic agents for diabetes mellitus have gained growing recognition for their potential anti-tumor effects through multi-pathway regulation, particularly in combination therapies, where they may enhance the efﬁcacy of traditional chemotherapy or targeted treatments for lung cancers. Therefore, in-depth investigation into the effects of various hypoglycemic agents on lung cancer, along with their underlying mechanisms, is of great signiﬁcance for developing more precise and effective treatment strategies, optimizing therapeutic outcomes, and improving patient survival rates. In the present review, we will summarize the recent progress of whether and how hypoglycemic agents could be potential complementary options for lung cancer treatment and explore the possible underlying mechanism. While examining the pharmacological proﬁle of metformin relevant with lung cancer treatment, this review also explores the unique idiosyncrasies of other commonly used agents in diabetes mellitus management.  \nKEYWORDS  \nchemoradiotherapy, diabetes mellitus, hypoglycemic drugs, immunotherapy, lung cancer, targeted therapy  \n1 Introduction  \nLung cancer (LC), characterized by its aggressive nature, ranks as the second most prevalent cancer globally, constituting 11.4% of all cancer cases. It is also the foremost cause of cancer-related fatalities, accounting for 18% of cancer mortality rates (1, 2), representing a major threat to human health. Lung cancer is histologically classiﬁed according to the WHO system, primarily into non−small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) . NSCLC accounts for 80%–85% of all lung cancer cases, while SCLC accou","cbCaimpdtSMsUvcx","https://ap.wps.com/l/cbCaimpdtSMsUvcx","pdf",1631287,12,"English","en",105,"# Introduction\n# Relationship between diabetes mellitus and lung cancer\n# Mechanistic basis of hypoglycemic drugs in lung cancer\n# Metformin and other hypoglycemic agents\n# Clinical implications and future directions","[{\"question\":\"Why are hypoglycemic drugs of interest in lung cancer treatment?\",\"answer\":\"Because accumulating evidence suggests diabetes mellitus medications may exert anti-tumor effects through multi-pathway regulation, particularly in combination therapies that could enhance standard treatments.\"},{\"question\":\"What kinds of lung cancer treatments are highlighted as the current clinical core options?\",\"answer\":\"Surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy are described as the main modalities in an individualized precision and immunotherapy era.\"},{\"question\":\"Which diabetes drug is specifically examined for lung cancer relevance?\",\"answer\":\"Metformin is singled out, alongside discussion of other commonly used hypoglycemic agents and their distinct characteristics in diabetes management.\"}]","The therapeutic value of antidiabetic drugs in lung cancer treatment: from clinical evidence to possible mechanisms | PDF",1790095193,[81,85,89,94],{"page_no":8,"url":82,"width":83,"height":84},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97352ed081be3122b1fd58fa9290ffcf.webp",983,1389,{"page_no":14,"url":86,"width":87,"height":88},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6cab75f8983162a1bac02115435b2995.webp",982,1388,{"page_no":90,"url":91,"width":92,"height":93},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3bcca66c619803cb7cea391bca65f363.webp",981,1386,{"page_no":19,"url":95,"width":96,"height":97},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2376443048057cbf82be95d08e7af77.webp",980,1385,{"code":4,"msg":99,"data":100},"ok",{"site_id":75,"language":74,"slug":101,"title":65,"keywords":102,"description":66,"schema_data":103,"social_meta":156,"head_meta":158,"extra_data":160,"updated_unix":161},"the-therapeutic-value-of-antidiabetic-drugs-in-lung-cancer-treatment-from-clinical-evidence-to-possible-mechanisms","",{"@graph":104,"@context":155},[105,118,138],{"@type":106,"itemListElement":107},"BreadcrumbList",[108,112,114,116],{"item":109,"name":110,"@type":111,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":113,"name":9,"@type":111,"position":14},"https://docshare.wps.com/document/",{"item":115,"name":40,"@type":111,"position":90},"https://docshare.wps.com/document/research-report/",{"item":117,"name":65,"@type":111,"position":19},"https://docshare.wps.com/document/the-therapeutic-value-of-antidiabetic-drugs-in-lung-cancer-treatment-from-clinical-evidence-to-possible-mechanisms/351665/",{"url":117,"name":65,"@type":119,"image":120,"author":125,"headline":65,"publisher":127,"fileFormat":130,"inLanguage":74,"description":66,"dateModified":131,"datePublished":132,"encodingFormat":130,"isAccessibleForFree":133,"interactionStatistic":134},"DigitalDocument",{"url":121,"@type":122,"width":123,"height":124},"https://docshare.wps.com/thumbnails/the-therapeutic-value-of-antidiabetic-drugs-in-lung-cancer-treatment-from-clinical-evidence-to-possible-mechanisms/351665.png","ImageObject",300,407,{"name":63,"@type":126},"Person",{"url":109,"name":128,"@type":129},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":135,"interactionType":136,"userInteractionCount":34},"InteractionCounter",{"@type":137},"ViewAction",{"@type":139,"mainEntity":140},"FAQPage",[141,147,151],{"name":142,"@type":143,"acceptedAnswer":144},"Why are hypoglycemic drugs of interest in lung cancer treatment?","Question",{"text":145,"@type":146},"Because accumulating evidence suggests diabetes mellitus medications may exert anti-tumor effects through multi-pathway regulation, particularly in combination therapies that could enhance standard treatments.","Answer",{"name":148,"@type":143,"acceptedAnswer":149},"What kinds of lung cancer treatments are highlighted as the current clinical core options?",{"text":150,"@type":146},"Surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy are described as the main modalities in an individualized precision and immunotherapy era.",{"name":152,"@type":143,"acceptedAnswer":153},"Which diabetes drug is specifically examined for lung cancer relevance?",{"text":154,"@type":146},"Metformin is singled out, alongside discussion of other commonly used hypoglycemic agents and their distinct characteristics in diabetes management.","https://schema.org",{"og:url":117,"og:type":157,"og:title":65,"og:site_name":128,"og:description":66},"article",{"robots":159,"canonical":117},"index,follow",{"doc_id":61,"site_id":75},1790448551]